Turn Therapeutics adds Martin Dewhurst to board of directors

Turn Therapeutics Inc. (NASDAQ: TTRX) appointed Martin Dewhurst to its board of directors, the clinical-stage biotechnology company announced. Dewhurst brings over 30 years of life sciences experience, with particular expertise in mergers and acquisitions.

The company develops targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases. Turn Therapeutics has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis.

Dewhurst spent much of his career at McKinsey & Company, where he co-led the firm's global life sciences practice. His expertise spans biopharmaceuticals, medical technology, genetics, and consumer health. He recently co-founded and led the McKinsey Health Institute, a nonprofit organization focused on global health challenges.

"Martin's appointment comes at a pivotal moment for Turn Therapeutics as we advance a disciplined, M&A-focused strategy to expand our pipeline and accelerate long-term value creation," said Bradley Burnam, chief executive officer of Turn Therapeutics.

Dewhurst currently serves as a senior advisor to PJT Partners, an investment and M&A advisory bank, and as an external partner to Lightrock, a growth-stage impact investor. He holds board positions including at Distalmotion, a Switzerland-based medical technology company focused on robotic surgery.

Dewhurst earned his undergraduate degree from Magdalen College, University of Oxford, and holds an MBA from INSEAD. The appointment information was provided in a company press release.

You May Also Be Interested In

• Mesoblast completes patient treatment in phase 3 back pain trial
• VICI Properties closes $1.75B senior unsecured notes offering
• Vivos Therapeutics posts 35% revenue gain but widens net loss